ARTICLE | Clinical News
Biogen Idec dropping baminercept for RA
October 10, 2008 12:36 AM UTC
Biogen Idec (NASDAQ:BIIB) said it will discontinue development of baminercept for rheumatoid arthritis (RA) after top-line data showed the compound missed the primary and all second endpoints in the P...